Back to top
more

Fusion Pharmaceuticals (FUSN)

(Real Time Quote from BATS)

$21.42 USD

21.42
754,785

+0.14 (0.63%)

Updated Apr 23, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Fusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Know

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) concluded the recent trading session at $21.24, signifying a -0.09% move from its prior day's close.

Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know

by Zacks Equity Research

In the most recent trading session, Fusion Pharmaceuticals Inc. (FUSN) closed at $21.36, indicating no shift from the previous trading day.

Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline

by Zacks Equity Research

Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.

Kinjel Shah headshot

Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates

by Kinjel Shah

AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.

Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

by Zacks Equity Research

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.

AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

by Zacks Equity Research

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.

ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

electroCore, Inc. (ECOR) delivered earnings and revenue surprises of -10.91% and 0.65%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.

Wall Street Analysts Believe Fusion Pharmaceuticals Inc. (FUSN) Could Rally 35.09%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Should You Add Marinus (MRNS) Stock to Your Portfolio Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.

Here's Why You Should Invest in Avadel (AVDL) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.

What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Benjamin Rains headshot

Finding the Best Cheap Stocks Under $10 to Buy in 2024

by Benjamin Rains

Let's take a look at the screen and a few of the over 50 highly-ranked cheap stocks to consider buying in January.

What Makes Fusion Pharmaceuticals Inc. (FUSN) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Fusion Pharmaceuticals Inc. (FUSN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.

Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use

by Zacks Equity Research

FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.

How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Fusion Pharmaceuticals (FUSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Brian Bolan headshot

Brian's Big Idea on Biotech

by Brian Bolan

A look at drugs for drug addiction and the biotech space.

Does Fusion Pharmaceuticals Inc. (FUSN) Have the Potential to Rally 47.76% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 47.8% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Shopify, Fusion Pharma, 3M in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

by Zacks Equity Research

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Kinjel Shah headshot

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

by Kinjel Shah

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Wall Street Analysts Predict a 149.52% Upside in Fusion Pharmaceuticals Inc. (FUSN): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 149.5% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Fusion Pharmaceuticals Inc. (FUSN) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Fusion Pharmaceuticals Inc. (FUSN) have what it takes to be a top stock pick for momentum investors? Let's find out.